Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01900665 · ClinicalTrials.gov registry record · Phase 3
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
A Phase 3 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 3
- Development phase
- 2,129
- Enrollment target
NCT01900665 is a Phase 3 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 2,129 participants.
The verdict
NCT01900665, a Phase 3 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 2,129 participants
- Enrollment target
Study Summary
To test the idea that solanezumab will slow the cognitive decline of Alzheimer's Disease (AD) as compared with placebo in participants with mild AD.
Interventions
- DRUG Placebo
- DRUG Solanezumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,129 participants |
| Start Date | 2013-07 |
| Est. Completion | 2017-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01900665
The ClinicalTrials.gov registry entry for NCT01900665 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 2,129 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01900665 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01900665 about?
NCT01900665 is a clinical study titled "Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo". To test the idea that solanezumab will slow the cognitive decline of Alzheimer's Disease (AD) as compared with placebo in participants with mild AD.
What is the current status of trial NCT01900665?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 2,129 participants. The study started on 2013-07. Estimated completion is 2017-02.
What interventions are being tested in trial NCT01900665?
The interventions under investigation include: Placebo (DRUG), Solanezumab (DRUG).
Who is sponsoring clinical trial NCT01900665?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.